Please assess the completion status of the following clinical trial:

Trial Title: Assessment of LCZ696 and Valsartan in Asian Patients With Salt-sensitive Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Written informed consent must be obtained before any study assessment is performed.~* Males and females of non-childbearing potential and of legal age (at least 18 years or older as defined by local law).~* Asian patients with mild to moderate essential hypertension, untreated or currently taking antihypertensive therapy with up to two drugs.~Key Exclusion Criteria:~* Women of child-bearing potential.~* History of angioedema, drug-related or otherwise~* History of hypersensitivity to LCZ696, valsartan, or drugs of similar chemical classes.~* Severe hypertension (grade 3 of WHO classification; msDBP ≥100 mmHg and/or msSBP ≥ 180 mmHg) at screening or at the end of the washout period.~* History or evidence of a secondary form of hypertension,~* Transient ischemic cerebral attack (TIA) during the 12 months prior to screening or any history of stroke.~* History of myocardial infarction, coronary bypass surgery or percutaneous coronary intervention (PCI) during 12 month prior to screening.~* Current or history of hypertensive retinopathy.~* Previous or current diagnosis of heart failure (NYHA Class II-IV).~* Clinically significant valvular heart disease at screening.~Other protocol defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LCZ696 followed by Valsartan (Type: EXPERIMENTAL): Period 1: LCZ696 400mg QD for 4 weeks then washout followed by Period 2: Valsartan 320mg QD for 4 weeks
- Valsartan followed by LCZ696 (Type: EXPERIMENTAL): Period 1: Valsartan 320mg QD for 4 weeks then washout followed by Period 2: LCZ696 400mg QD for 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).